Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease
What is the purpose of this trial?
This is a phase II open-label study of the activity and safety of trastuzumab in patients with vulvar Paget's disease with overexpression of HER2 on biopsy.
- 18 Years - N/A
- Genentech, Inc.
- August 2011
- Last Updated:
- June 12, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT01427244